Latest Period
n/a
Security Snapshot
Passage BIO, Inc. - Common Stock, par value $0.0001 per share (PASG) Institutional Ownership
CUSIP: 702712100
13F Institutional Holders and Ownership History from Q1 2020 to Q4 2025
Institutions Reporting
Shares (Excl. Options)
Price
$0.39
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- PASG on Nasdaq
- Shares outstanding
- 3,182,163
- SEC-reported price per share
- $0.39
- Insider filing price
- $0.39
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PASG - Passage BIO, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 702712100.
- Latest finished 13F holder period is not available.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
- SEC-reported value moved from $702,031 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
702712100
Latest holder period
n/a
13F holders
13D/G owners
3
CIK / CUSIP context first
PASG full holder history
Passage BIO, Inc. SEC filings
Passage BIO, Inc. company facts
Passage BIO, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 702712100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
PASG
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Erste Asset Management GmbH | 4.4% | -20% | $810,414 | -$166,650 | 2,455,800 | -17% | Erste Asset Management GmbH | 31 Mar 2024 |
| Lynx1 Capital Management LP | 20% | +31% | $243,245 | -$3,366,967 | 623,704 | -93% | LYNX1 CAPITAL MANAGEMENT LP | 30 Sep 2025 |
| ORBIMED ADVISORS LLC | 4.2% | -45% | $53,029 | -$44,595 | 132,473 | -46% | ORBIMED ADVISORS LLC | 22 Jul 2025 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Latest
n/a
Rows shown
1-24 of 24
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$9,207 | $0.39 | 0 |
| 2025 Q3 | 87,426 | $702,031 | -$13,025,438 | $8.03 | 1 |
| 2025 Q2 | 32,555,495 | $13,025,837 | -$494,591 | $0.40 | 36 |
| 2025 Q1 | 36,319,532 | $12,823,290 | -$494,907 | $0.35 | 40 |
| 2024 Q4 | 37,629,720 | $21,576,538 | -$666,122 | $0.57 | 43 |
| 2024 Q3 | 38,667,152 | $27,063,600 | -$1,516,413 | $0.70 | 43 |
| 2024 Q2 | 40,276,764 | $31,993,150 | -$250,391 | $0.79 | 41 |
| 2024 Q1 | 40,302,560 | $54,403,729 | +$10,300,380 | $1.35 | 47 |
| 2023 Q4 | 32,758,119 | $33,084,893 | +$1,665,873 | $1.01 | 49 |
| 2023 Q3 | 32,389,479 | $21,315,264 | -$689,693 | $0.66 | 48 |
| 2023 Q2 | 33,366,974 | $31,393,818 | -$2,067,482 | $0.94 | 53 |
| 2023 Q1 | 35,544,402 | $34,036,927 | -$2,408,274 | $0.96 | 55 |
| 2022 Q4 | 37,376,459 | $51,570,790 | -$593,641 | $1.38 | 64 |
| 2022 Q3 | 1,232,073 | $1,538,826 | -$4,445,404 | $1.42 | 8 |
| 2022 Q2 | 42,200,841 | $99,586,412 | -$2,254,627 | $2.36 | 77 |
| 2022 Q1 | 42,974,148 | $133,214,830 | -$35,203,815 | $3.10 | 99 |
| 2021 Q4 | 43,736,986 | $277,681,358 | -$20,365,609 | $6.35 | 94 |
| 2021 Q3 | 42,080,753 | $419,127,083 | -$27,972,780 | $9.96 | 98 |
| 2021 Q2 | 42,094,204 | $557,333,406 | -$6,360,822 | $13.24 | 99 |
| 2021 Q1 | 44,993,194 | $786,465,406 | +$223,951,633 | $17.48 | 88 |
| 2020 Q4 | 31,980,456 | $817,765,848 | +$41,938,422 | $25.57 | 71 |
| 2020 Q3 | 30,776,051 | $403,488,177 | -$23,838,864 | $13.11 | 68 |
| 2020 Q2 | 31,598,964 | $862,660,732 | +$80,586,836 | $27.33 | 66 |
| 2020 Q1 | 29,151,958 | $458,206,000 | +$457,418,009 | $15.75 | 45 |